Is Nivolumab reimbursed by medical insurance?

Nivolumab (Nivolumab) is indicated for the treatment of unresectable or metastatic melanoma, melanoma as adjuvant therapy, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classic Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial cancer, microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, hepatocellular carcinoma and esophageal cancer.

The indications for classic Hodgkin lymphoma, microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, and hepatocellular carcinoma were approved under accelerated approval based on overall response rate. Nivolumab is also approved for the treatment of HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma when used in combination with fluoropyrimidine- and platinum-containing chemotherapy regimens. Nivolumab is indicated for the treatment of patients ≥12 years of age with unresectable or metastatic melanoma when used in combination with relatlimab. The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T cells and inhibit the action of these cells. Tumor cells express PD-L1 and PD-L2. Nivolumab binds to PD-1, preventing the inhibitory effect of PD-L1 and PD-L2 on T cells and restoring the patient's tumor-specific T cell response.

The generic drug nivolumab is currently on the market in China, but it has not yet been included in medical insurance and cannot be reimbursed. This drug is a strictly controlled drug, and its purchase channels are restricted. Specifications The price of each box of 40mg/4ml may be around 4,000 yuan. The Turkish version of the nivolumab generic drug listed overseas may cost more than RMB 2,000 per box of 40mg/4ml (the price may fluctuate due to exchange rates). Currently, there is no generic version of nivolumab available on the market. For more drug information and specific prices, please consult a medical consultant.